These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 2705449)

  • 1. Accelerated removal of deferoxamine mesylate-chelated aluminum by charcoal hemoperfusion in hemodialysis patients.
    Delmez J; Weerts C; Lewis-Finch J; Windus D; Slatopolsky E
    Am J Kidney Dis; 1989 Apr; 13(4):308-11. PubMed ID: 2705449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferoxamine and coated charcoal hemoperfusion to remove aluminum in dialysis patients.
    McCarthy JT; Milliner DS; Schmidt DF; Schniepp BJ; Kurtz SB; Johnson WJ
    Kidney Int; 1988 Dec; 34(6):804-8. PubMed ID: 3210542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid removal of DFO-chelated aluminum during hemodialysis using polysulfone dialyzers.
    Molitoris BA; Alfrey AC; Alfrey PS; Miller NL
    Kidney Int; 1988 Jul; 34(1):98-101. PubMed ID: 3172641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminum removal with hemodialysis, hemofiltration and charcoal hemoperfusion in uremic patients after desferrioxamine infusion. A comparison of efficiency.
    Weiss LG; Danielson BG; Fellström B; Wikström B
    Nephron; 1989; 51(3):325-9. PubMed ID: 2918944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis.
    Vasilakakis DM; D'Haese PC; Lamberts LV; Lemoniatou E; Digenis PN; De Broe ME
    Kidney Int; 1992 May; 41(5):1400-7. PubMed ID: 1614055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferoxamine and aluminum clearance in pediatric hemodialysis patients.
    Ogborn MR; Dorcas VC; Crocker JF
    Pediatr Nephrol; 1991 Jan; 5(1):62-4. PubMed ID: 2025542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
    Vogelsang U
    Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Removal of aluminum from chronic dialysis patients by administration of desferrioxamine and dialysis.
    Ono T; Iwamoto N; Kataoka H; Taniguchi Y; Sakai Y; Kunitomo T
    ASAIO Trans; 1986; 32(1):52-7. PubMed ID: 3778761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of aluminum overload using a cartridge with immobilized desferrioxamine.
    Anthone S; Ambrus CM; Kohli R; Min I; Anthone R; Stadler A; Stadler I; Vladutiu A
    J Am Soc Nephrol; 1995 Oct; 6(4):1271-7. PubMed ID: 8589296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Removal of chelated aluminium during haemodialysis using polysulphone high-flux dialysers.
    Aarseth HP; Ganss R
    Nephrol Dial Transplant; 1990; 5(11):942-4. PubMed ID: 2127830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of aluminum during hemodialysis: effect of different dialyzer membranes.
    Muirhead N; Hollomby DJ; Leung FY; Mitton R; Henderson AR; Keown PA; Stiller CR
    Am J Kidney Dis; 1986 Jul; 8(1):51-5. PubMed ID: 3728462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a single session in-series hemoperfusion and hemodialysis in the management of carprofen overdose in two dogs.
    Fick ME; Messenger KM; Vigani A
    J Vet Emerg Crit Care (San Antonio); 2020 Mar; 30(2):226-231. PubMed ID: 32128985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation.
    Molitoris BA; Alfrey PS; Miller NL; Hasbargen JA; Kaehney WD; Alfrey AC; Smith BJ
    Kidney Int; 1987 Apr; 31(4):986-91. PubMed ID: 3586503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of aluminum-related bone disease and treatment of aluminum toxicity with deferoxamine.
    Coburn JW; Norris KC
    Semin Nephrol; 1986 Dec; 6(4 Suppl 1):12-21. PubMed ID: 3299588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis.
    Chang TM; Barre P
    Lancet; 1983 Nov; 2(8358):1051-3. PubMed ID: 6138600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solute, amino acid, and hormone changes with coated charcoal hemoperfusion in uremia.
    Winchester JF; Ratcliffe JG; Carlyle E; Kennedy AC
    Kidney Int; 1978 Jul; 14(1):74-81. PubMed ID: 682427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of an iron supplement on serum aluminum level and desferrioxamine mobilization test in hemodialysis patients.
    Huang JY; Wu MS; Wu CH
    Ren Fail; 2001 Nov; 23(6):789-95. PubMed ID: 11777318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of body iron stores on serum aluminum level in hemodialysis patients.
    Huang JY; Huang CC; Lim PS; Wu MS; Leu ML
    Nephron; 1992; 61(2):158-62. PubMed ID: 1630539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mass transfer characteristics of hollow-fiber dialyzers and hemoperfusion devices.
    Cooney DO; Daly JS
    Artif Organs; 1979 Aug; 3(3):253-7. PubMed ID: 533416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.